Armistice Capital LLC Acquires 360,000 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Armistice Capital LLC increased its holdings in Supernus Pharmaceuticals by 7.4% to own a total of 5,196,000 shares, making it the firm's second-largest position.
• Analysts have raised their price targets for Supernus, with Cantor Fitzgerald setting a new target of $46.00 and a consensus average target of $43.00 reflecting a "Moderate Buy" rating.
• Insider transactions include CEO Jack A. Khattar selling 1,000 shares at $45.00 and Director Bethany Sensenig selling 5,369 shares at $42.25, indicating ongoing insider trading activity.

Armistice Capital LLC boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,196,000 shares of the specialty pharmaceutical company's stock after purchasing an additional 360,000 shares during the period. Supernus Pharmaceuticals comprises 2.6% of Armistice Capital LLC's portfolio, making the stock its 2nd largest position. Armistice Capital LLC owned 9.28% of Supernus Pharmaceuticals worth $170,169,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SUPN. Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $25,000. Financial Management Professionals Inc. purchased a new position in Supernus Pharmaceuticals in the first quarter valued at about $30,000. Versant Capital Management Inc boosted its holdings in Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 1,109 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Supernus Pharmaceuticals in the first quarter valued at about $41,000. Finally, GF Fund Management CO. LTD. acquired a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $42,000.

Insider Transactions at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 1,000 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $45.00, for a total value of $45,000.00. Following the sale, the chief executive officer directly owned 1,071,459 shares in the company, valued at $48,215,655. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bethany Sensenig sold 5,369 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The disclosure for this sale can be found here. Insiders sold 179,606 shares of company stock worth $7,617,005 over the last quarter. Insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded up $0.39 on Wednesday, reaching $44.93. 553,192 shares of the company were exchanged, compared to its average volume of 955,866. The company's 50-day moving average is $37.15 and its two-hundred day moving average is $33.98. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of 39.07 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $45.94.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SUPN. Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Piper Sandler increased their target price on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a report on Friday, August 29th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $43.00.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.